Table 4. Univariate and multivariate analysis of prognostic factors for overall survival.

Clinicopathological factor		Univariate			Multivariate
		HR	95% CI	p-value	HR	95% CI	p-value
FIGO stage	III vs. IV	1.39	0.88-2.19	0.16	1.31	0.81-2.12	0.28
Histologic subtype	Serous vs. non-serous	1.05	0.58-1.91	0.84	0.84	0.44-1.62	0.61
Neoadjuvant chemotherapy
No. of cycles	≤4 vs. 5≤	1.11	0.67-1.84	0.69	1.48	0.85-2.55	0.16
Regimen	Taxane based vs. non-taxane	1.01	0.64-1.59	0.98	1.02	0.61-1.70	0.94
Interval debulking surgery
Systematic lymphadenectomy	Done vs. not done	0.89	0.55-1.45	0.65	1.1	0.64-1.88	0.74
Excision of other organ(s)	Done vs. not done	0.75	0.52-1.08	0.12	0.86	0.56-1.32	0.49
Ascites cytology	Negative vs. positive	1.29	0.88-1.87	0.19	1.21	0.82-1.77	0.33
Lymph node metastasis	No vs. yes	0.89	0.67-1.2	0.44	0.99	0.70-1.41	0.97
Gross residual lesion	No vs. yes	4.03	2.46-6.61	<0.001	4.14	2.39-7.16	<0.001

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.